Celltrion, Inc. (KRX:068270)
204,000
-3,000 (-1.45%)
Last updated: Apr 29, 2026, 2:43 PM KST
Celltrion Revenue
In the year 2025, Celltrion had annual revenue of 4.16T KRW with 17.01% growth. Celltrion had revenue of 1.33T in the quarter ending December 31, 2025, with 25.06% growth.
Revenue
4,162.50B
Revenue Growth
+17.01%
P/S Ratio
10.42
Revenue / Employee
1.55B
Employees
2,680
Market Cap
43.39T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4,162.50B | 605.19B | 17.01% |
| Dec 31, 2024 | 3,557.30B | 1,380.87B | 63.45% |
| Dec 31, 2023 | 2,176.43B | -107.54B | -4.71% |
| Dec 31, 2022 | 2,283.97B | 390.57B | 20.63% |
| Dec 31, 2021 | 1,893.40B | 44.29B | 2.39% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,814.00B |
| ALTEOGEN | 215.86B |
| Samsung Epis Holdings | 1,510.14B |
| SK Biopharmaceuticals | 706.74B |
| HLB Co., Ltd. | 84.17B |
| LigaChem Biosciences | 141.55B |
| Peptron | 5.63B |
| Voronoi | 7.51B |
Celltrion News
- 7 days ago - Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW) - Benzinga
- 6 weeks ago - Celltrion Enters Contract Manufacturing Agreement With Global Pharmaceutical Company - Nasdaq
- 6 weeks ago - Celltrion Announces Commercial Availability In US Of AVTOZMA SC, Tocilizumab Biosimilar - Nasdaq
- 2 months ago - Celltrion Reports Post-hoc Analysis From LIBERTY Studies - Nasdaq
- 5 months ago - FDA Clears New Prefilled Syringe Of Celltrion's OMLYCLO, Interchangeable Biosimilar To XOLAIR - Nasdaq
- 7 months ago - FDA Approves Celltrion's EYDENZELT, Biosimilar To EYLEA, For Multiple Retinal Conditions - Nasdaq
- 7 months ago - Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal - The Times of India
- 7 months ago - Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence - GuruFocus